The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | ZUMA-14 updates and the promise of dual antigen targeting approaches
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some updates from the ZUMA-14 trial (NCT04002401) investigating the safety and efficacy of rituximab in combination with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). Dr Patel comments on the overall response rate (ORR) and progression-free survival (PFS) observed, and further highlights the promise of dual antigen targeting treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
